Cadila Pharmaceuticals
Biosimilar developer, India. 2 development products across 2 molecules: filgrastim, insulin human.
First approval in the Atlas: Oct 2013, Cadila Pharmaceuticals (INN only), filgrastim (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Filgrastim | Cadila Pharmaceuticals filgrastim | · | · | · | · | Oct 2013 | · |
| Insulin human | Cadila Pharmaceuticals human insulin | · | · | · | · | Nov 2024 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOOct 2013Cadila Pharmaceuticals (INN only), filgrastim
- CDSCONov 2024Cadila Pharmaceuticals (INN only), insulin human
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.